Biogen Inc. Announces Board and Executive Changes

Ticker: BIIB · Form: 8-K · Filed: 2025-01-15T00:00:00.000Z

Sentiment: neutral

Topics: executive-changes, board-of-directors, appointments, departures

Related Tickers: BIIB

TL;DR

Biogen shakes up board, names new exec; Sandage out, Singhal in.

AI Summary

Biogen Inc. announced on January 13, 2025, changes in its board of directors and executive compensation. Specifically, Dr. Al Sandage, Jr. resigned from the Board of Directors, and the company appointed Dr. Priya Singhal as Executive Vice President, Head of Global Product Strategy and Commercialization. The filing also details updates to the company's compensatory arrangements for its named executive officers.

Why It Matters

Changes in board composition and executive leadership can signal shifts in company strategy or operational focus, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Executive and board changes, especially resignations, can introduce uncertainty regarding future strategy and leadership stability.

Key Players & Entities

FAQ

Who resigned from Biogen's Board of Directors?

Dr. Al Sandage, Jr. resigned from the Board of Directors.

What is Dr. Priya Singhal's new role at Biogen?

Dr. Priya Singhal has been appointed Executive Vice President, Head of Global Product Strategy and Commercialization.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is January 13, 2025.

What other items are covered in this 8-K filing besides director and officer changes?

The filing also covers the election of directors and compensatory arrangements of certain officers.

In which state is Biogen Inc. incorporated?

Biogen Inc. is incorporated in Delaware.

From the Filing

0001193125-25-006578.txt : 20250115 0001193125-25-006578.hdr.sgml : 20250115 20250115080018 ACCESSION NUMBER: 0001193125-25-006578 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250113 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250115 DATE AS OF CHANGE: 20250115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 25531203 BUSINESS ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC. DATE OF NAME CHANGE: 20070427 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 8-K 1 d830064d8k.htm 8-K 8-K false 0000875045 0000875045 2025-01-13 2025-01-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025   Biogen Inc. (Exact name of registrant as specified in its charter)   Delaware   0-19311   33-0112644 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   225 Binney Street , Cambridge , Massachusetts 02142 (Address of principal executive offices; Zip Code) Registrant’s telephone number, including area code: (617) 679-2000 Not Applicable (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class    Trading Symbol(s)    Name of each exchange on which registered Common Stock, $0.0005 par value    BIIB    The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 13, 2025, Biogen Inc. (the “Company”) appointed Sean Godbout as Vice President, Chief Accounting Officer & Global Corporate Controller and designated Mr. Godbout as the Company’s principal accounting officer, in each case effective as of March 1, 2025. In conne

View on Read The Filing